A paper describing the potentials of Nichi Glucan as a vaccine adjuvant to COVID-19 has been published in Human Vaccines and Immunotherapeutics, a journal sponsored by the International Society of Vaccines.
Clinical studies in Covid-19 and its variants to tackle the pandemic, recommended.
To read the press release in Business Wire, click here.
Please visit nichiglucan.com for more information about Nichi Glucan.
![ワクチンアジュベントとしてのニチグルカンの可能性](https://gncorporation.com/gnc/wp-content/uploads/2022/06/vaccine-adjyuvant.gif)